Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Nektar Therapeutics Company Profile (NASDAQ:NKTR)

Consensus Ratings for Nektar Therapeutics (NASDAQ:NKTR) (?)
Ratings Breakdown: 2 Sell Rating(s), 1 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Hold (Score: 2.38)
Consensus Price Target: $15.71 (30.19% upside)

Analysts' Ratings History for Nektar Therapeutics (NASDAQ:NKTR)
Show:
DateFirmActionRatingPrice TargetDetailsShare
9/17/2014Bank of AmericaReiterated RatingUnderperform$10.00 -> $11.00ViewTweet This Rating  Share This Rating on StockTwits
9/16/2014Brean CapitalBoost Price TargetBuy$18.00 -> $20.00ViewTweet This Rating  Share This Rating on StockTwits
8/21/2014Roth CapitalReiterated RatingBuyViewTweet This Rating  Share This Rating on StockTwits
8/11/2014Roth CapitalReiterated RatingBuyViewTweet This Rating  Share This Rating on StockTwits
8/4/2014ZacksReiterated RatingUnderperform -> Underperform$11.00ViewTweet This Rating  Share This Rating on StockTwits
7/18/2014ZacksDowngradeNeutral -> Underperform$10.00ViewTweet This Rating  Share This Rating on StockTwits
6/26/2014Ladenburg ThalmannInitiated CoverageBuy$20.00ViewTweet This Rating  Share This Rating on StockTwits
6/13/2014MKM PartnersReiterated RatingNeutral$13.00ViewTweet This Rating  Share This Rating on StockTwits
5/15/2014Jefferies GroupReiterated RatingBuy$15.00ViewTweet This Rating  Share This Rating on StockTwits
5/7/2014Jefferies GroupReiterated RatingBuy$15.00ViewTweet This Rating  Share This Rating on StockTwits
4/29/2014Jefferies GroupReiterated RatingBuy$15.00ViewTweet This Rating  Share This Rating on StockTwits
4/21/2014Jefferies GroupInitiated CoverageBuy$15.00ViewTweet This Rating  Share This Rating on StockTwits
2/27/2014MKM PartnersDowngradeBuy -> Neutral$13.00ViewTweet This Rating  Share This Rating on StockTwits
2/27/2014Jefferies GroupBoost Price Target$11.00 -> $12.00ViewTweet This Rating  Share This Rating on StockTwits
2/3/2014Brean CapitalBoost Price Target$14.00 -> $18.00ViewTweet This Rating  Share This Rating on StockTwits
11/26/2013Piper JaffrayInitiated CoverageOverweight$20.00ViewTweet This Rating  Share This Rating on StockTwits
9/30/2013JPMorgan Chase & Co.Lower Price TargetOverweight$15.00 -> $14.00ViewTweet This Rating  Share This Rating on StockTwits
9/27/2013Cowen and CompanyReiterated RatingBuy$17.00ViewTweet This Rating  Share This Rating on StockTwits
9/27/2013Brean CapitalReiterated RatingBuy$17.00 -> $14.00ViewTweet This Rating  Share This Rating on StockTwits
9/27/2013William BlairReiterated RatingOutperformViewTweet This Rating  Share This Rating on StockTwits
9/27/2013MKM PartnersLower Price TargetBuy$14.00 -> $13.00ViewTweet This Rating  Share This Rating on StockTwits
9/27/2013Jefferies GroupReiterated RatingHold$11.00ViewTweet This Rating  Share This Rating on StockTwits
9/12/2013Cowen and CompanyInitiated CoverageOutperform$17.00ViewTweet This Rating  Share This Rating on StockTwits
8/15/2013Brean CapitalBoost Price TargetBuy$14.00 -> $17.00ViewTweet This Rating  Share This Rating on StockTwits
6/20/2013MKM PartnersBoost Price TargetBuy$13.00 -> $14.00ViewTweet This Rating  Share This Rating on StockTwits
3/20/2013MKM PartnersReiterated RatingBuy$13.00ViewTweet This Rating  Share This Rating on StockTwits
3/1/2013Deutsche BankLower Price TargetBuy$13.00 -> $12.00ViewTweet This Rating  Share This Rating on StockTwits
1/15/2013Lazard LtdInitiated CoverageBuy$15.00ViewTweet This Rating  Share This Rating on StockTwits
11/13/2012Bank of AmericaReiterated RatingUnderperformViewTweet This Rating  Share This Rating on StockTwits
11/12/2012Jefferies GroupDowngradeBuy -> Hold$10.00 -> $8.00ViewTweet This Rating  Share This Rating on StockTwits
10/2/2012Deutsche BankReiterated RatingBuy -> BuyViewTweet This Rating  Share This Rating on StockTwits
(Data available from 10/1/2012 forward)
Discuss Nektar Therapeutics